Corvus Pharmaceuticals (FRA:C17) Accounts Payable: €4.06 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:C17 Corvus Pharmaceuticals Inc FRA:C17
34 GF Score
Price €11.98
! 1 Warning Sign
View Full Analysis

What is Corvus Pharmaceuticals Accounts Payable?

Corvus Pharmaceuticals FRA:C17 -5.03% 34 Accounts Payable is €4.06 Mil as of Mar. 2026. GuruFocus rates FRA:C17 with a GF Score™ of 34/100. The stock has 1 warning sign investors should review.

Corvus Pharmaceuticals's Accounts Payable for the quarter that ended in Mar. 2026 was €4.06 Mil.

Corvus Pharmaceuticals's quarterly Accounts Payable increased from Sep. 2025 (€1.68 Mil) to Dec. 2025 (€2.13 Mil) and increased from Dec. 2025 (€2.13 Mil) to Mar. 2026 (€4.06 Mil).

Corvus Pharmaceuticals's annual Accounts Payable increased from Dec. 2023 (€1.40 Mil) to Dec. 2024 (€2.47 Mil) but then declined from Dec. 2024 (€2.47 Mil) to Dec. 2025 (€2.13 Mil).

Corvus Pharmaceuticals Accounts Payable Related Terms

Corvus Pharmaceuticals Accounts Payable Historical Data

* Premium members only.

The historical data trend for Corvus Pharmaceuticals's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corvus Pharmaceuticals Accounts Payable Chart

Corvus Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.39 1.87 1.40 2.47 2.13

Corvus Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.21 2.72 1.68 2.13 4.06
FRA:C17
34GF Score
Corvus Pharmaceuticals Inc FRA:C17
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corvus Pharmaceuticals Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of €4.06 Mil mean?
Corvus Pharmaceuticals (FRA:C17) has a Accounts Payable of €4.06 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Corvus Pharmaceuticals and its competitors.
Is Corvus Pharmaceuticals' Accounts Payable too high?
Corvus Pharmaceuticals' current Accounts Payable is €4.06 Mil. Overall, Corvus Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Corvus Pharmaceuticals' Accounts Payable compare to LXRX and CGEM?
Corvus Pharmaceuticals' Accounts Payable of €4.06 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Corvus Pharmaceuticals and its competitors. Corvus Pharmaceuticals's current Accounts Payable is €4.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corvus Pharmaceuticals stock overvalued right now?
Corvus Pharmaceuticals (FRA:C17) has a current Accounts Payable of €4.06 Mil. The current Accounts Payable is €4.06 Mil. Corvus Pharmaceuticals' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Corvus Pharmaceuticals (FRA:C17), the current Accounts Payable is €4.06 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Corvus Pharmaceuticals Business Description

Other Exchanges CRVS:USAC17:Germany
Address 901 Gateway Boulevard, Third Floor, South San Francisco, CA, USA, 94080
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
34GF Score

Get the complete analysis for FRA:C17

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.98
Price